These approaches include consolidation and maintenance therapy, intraperitoneal (IP) administration of cytotoxic agents, new combination chemotherapy regimens, development of new cytotoxic agents, and molecular-targeted therapies (beyond tumor DNA, the classical target of cytotoxic drugs). IP chemotherapy, ...
“I have known John when he was a Manager at Pinkerton over 20 years ago. Back then, he pioneered the anti-software piracy raids, and he’s still into it – supervising various types of IP investigations for over 25 years now. After establishing IP2Manila, he has been designing long and...
“As an administration, we believe in strong intellectual property rights, just to make it clear,” USPTO director Kathi Vidal said today, May 3, kicking off her session at the INTA Annual Meeting in Washington DC. “On the patent side, there are some things we need to accompl...
Patent linkage is another mechanism to enforce drugs’ patent – it links drugs registration to patents, so that drug administration authorities do not approve the registration of a drug that would infringe on a patent. Patent ...
SAIP has put in place an ambitious reform agenda and is revamping the administration of the Kingdom’s national IP environment; continued positive efforts occurred in 2023 Saudi Arabia's IP Weaknesses Pharmaceutical patent protection and linkage mechanism in effect suspended through SFDA actions in 20...
The China National Intellectual Property Administration(CNIPA), China’s top IP regulator, recently released on its website the "2023 China Patent Survey Report"... China issues the first-ever "Guidelines for Handling Criminal Cases of Infringing upon Trade Secrets" ...
The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensation, and administration of antineoplastic therapy, and the agents, both commercially available and investi...
“drugs, biologics (including vaccines) or devices for the prevention, diagnosis or treatment of human disease.” The administration has claimed this is being done “to expand patient access to products that emerge from NIH-owned inventions.” The guidelines apply to all licenses, exclusive and ...
The Beijing court urged the administration to revoke its decision and make a new one. Both the Chinese and US sides were unhappy with the result, so they appealed to a higher court. After investigation and research, the IP ...
The accessibility of the therapeutic cells to their expectable target site is strongly dependent on the route of administration used. Therefore, the MSCs delivery should be tailored to the lesion kind and custom- ized to the mechanism of action of MSCs. Currently, the intravenous injection (IV) ...